Insights on Hepatocellular Carcinoma in Saudi Arabia

Althubiti, Mohammad; Alfayez, Mohammad

doi:10.1007/978-3-030-78737-0_16

Cited by 2 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 However, since the initial epidemiological studies showing a high prevalence of HBV were conducted on children who are now adults, it is reasonable to assume that about 20% of these individuals will probably develop cirrhosis with an annual risk of 1% to 4% for HCC. 9,13 Additionally, the prevalence of HCV infection in Saudi Arabia ranges from 0.4% to 1.1% with an average prevalence of around 0.3% thereby further increasing the cases of HCC and related morbidity and mortality. [13][14][15] Between 1996 and 2006, there has been 437,000 confirmed HCV cases in Saudi Arabia, estimated to increase to 103,000 cases by 2030, with a corresponding increase in HCC, decompensated and compensated liver cirrhosis, and liver-related mortality.…”

Section: Epidemiology and Risk Factors For Hcc In Saudi Arabiamentioning

confidence: 99%

“…HCC comprises more than three-fourth of the liver cancer cases in Saudi Arabia with an age-standardized incidence rate (ASIR) of 5.2 per 100,000 people as compared with an ASIR of 4.7 per 100,000 people for the Western Asia region. 1,2,[7][8][9][10] The major obstacle to early diagnosis and effective treatment of patients with HCC in Saudi Arabia is the fact that most patients with HCC remain asymptomatic until advanced stage. 4 As such, screening for high-risk individuals is imperative for early identification.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia

Alolyan,

Alshammari,

Arabi

et al. 2024

JHC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world associated with high morbidity and mortality. Despite being a significant healthcare burden there is limited information on the unmet needs and current treatment practices for intermediate and advanced-stage HCC in Saudi Arabia. This article analyzes the gaps and provides expert consensus on the management strategies for unresectable HCC in Saudi Arabia. A pre-meeting online questionnaire, comprising 20 objective questions about the treatment landscape and diagnosis of HCC in Saudi Arabia, was distributed to experts in the field of HCC management. An advisory board meeting including a panel of 13 experts was held in September 2022 where the responses to the survey questionnaire were reviewed and discussed. The survey results and experts’ discussion highlighted the growing incidence of liver cancer in Saudi Arabia. HCC comprised the majority of all liver cancer cases due to rising rates of chronic viral infections and lifestyle-related risk factors. Most physicians in Saudi Arabia follow the Barcelona Clinic Liver Cancer guidelines as a prognostic tool for the detection and staging of patients with HCC. Most of the patients with HCC in Saudi Arabia are diagnosed in the intermediate or advanced stages with poor prognoses and limited therapeutic options. Establishing evidence-based surveillance techniques, a multidisciplinary approach to diagnosis, and better accessibility of treatment options is vital for the management of HCC in Saudi Arabia.

show abstract